Form 8-K - Current report:
SEC Accession No. 0001753926-26-000097
Filing Date
2026-01-13
Accepted
2026-01-13 08:30:59
Documents
16
Period of Report
2026-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g085079_8k.htm   iXBRL 8-K 46153
2 EXHIBIT 4.1 g085079_ex4-1.htm EX-4.1 83693
3 EXHIBIT 10.1 g085079_ex10-1.htm EX-10.1 479514
4 EXHIBIT 99.1 g085079_ex99-1.htm EX-99.1 22608
8 GRAPHIC image_001.jpg GRAPHIC 2501
  Complete submission text file 0001753926-26-000097.txt   926495

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pths-20260112.xsd EX-101.SCH 3011
6 XBRL LABEL FILE pths-20260112_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE pths-20260112_pre.xml EX-101.PRE 22356
18 EXTRACTED XBRL INSTANCE DOCUMENT g085079_8k_htm.xml XML 3346
Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41964 | Film No.: 26528522
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)